Trial Profile
Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs OCV 101 (Primary) ; Gemcitabine
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 16 Feb 2011 New trial record